The combination of drug treatment and zinc restores p53 oncosuppressive activity, thus reducing the chemoresistance of mutant p53-carrying cancer cells with increased cancer cell death in vitro and inhibition of tumor growth in vivo [12–16]. Here, TP53 is linked to cancer.